Caxton Associates (New York)’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Caxton Associates (New York)’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-18,093	Closed	-$98.2K	–	671
2022 Q4	$98.2K	Buy	+18,093	New	+$152K	0.01%	420
2022 Q3	–	Sell	-21,388	Closed	-$106K	–	714
2022 Q2	$106K	Buy	+21,388	New	+$118K	0.01%	510
2020 Q2	–	Sell	-13,388	Closed	-$148K	–	664
2020 Q1	$148K	Buy	+13,388	New	+$250K	0.03%	371

Other funds holding GTHX

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Caxton Associates (New York)'s GTHX Position: Q1 2023 in Review

Caxton Associates (New York) sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2023, closing a stake of 18,093 shares — an estimated $98.2K sold.

Caxton Associates (New York) first reported a position in GTHX in Q1 2020 and held it in 3 quarters. The position peaked at $148K in Q1 2020. 96 funds tracked by Wall St. Rank hold GTHX as of Q1 2023.

Caxton Associates (New York) reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Caxton Associates (New York) sold 18,093 G1 Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $98.2K.
Caxton Associates (New York) first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2020 and held it in 3 quarters.
Caxton Associates (New York)'s G1 Therapeutics, Inc. Common Stock position peaked at $148K in Q1 2020.
96 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.